Valuation: Lineage Cell Therapeutics, Inc.

Market Cap 33Cr 29Cr 26Cr 25Cr 46Cr 3.1TCr 47Cr 317.44Cr 122.99Cr 1.52TCr 122.62Cr 119.97Cr 5.3TCr P/E 2026 *
-18.7x
P/E 2027 * -14.3x
Enterprise Value 33Cr 29Cr 26Cr 25Cr 46Cr 3.1TCr 47Cr 317.44Cr 122.99Cr 1.52TCr 122.62Cr 119.97Cr 5.3TCr EV / Sales 2026 *
18.2x
EV / Sales 2027 * 18.1x
Free-Float
95.07%
Yield 2026 *
-
Yield 2027 * -
1 day-0.76%
1 week+3.17%
Current month-0.76%
1 month+3.17%
3 months-18.24%
6 months-20.73%
Current year-22.16%
1 week 1.2
Extreme 1.2
1.37
1 month 1.18
Extreme 1.18
1.37
Current year 1.18
Extreme 1.18
1.98
1 year 0.91
Extreme 0.9068
2.09
3 years 0.37
Extreme 0.3651
2.09
5 years 0.37
Extreme 0.3651
2.85
10 years 0.37
Extreme 0.3651
4
Manager TitleAgeSince
Chief Executive Officer 54 17/09/2018
Director of Finance/CFO 50 14/11/2022
Chief Operating Officer - 01/12/2010
Director TitleAgeSince
Director/Board Member 60 01/07/2009
Director/Board Member 68 11/04/2014
Chairman 60 27/04/2024
Date Insider Type Main position Quantity % Market Cap.
12/03Buy

Chief Executive Officer

15,000 0.0065%
05/03Free

Chief Executive Officer

32,50,000 1.4110%
05/03Free

General Counsel

9,00,000 0.3907%
Change 5-day change 1-year change 3-year change Capi.($)
-0.76%+3.17%+44.81%-7.80% 33Cr
+3.08%+9.20%-0.42%+5.47% 4.72TCr
+0.12%+10.45%+408.29%+598.88% 3.98TCr
+5.17%+9.47%+24.96%-8.08% 3.22TCr
+2.02%+4.91%+18.59%+60.76% 3.17TCr
+0.69%+8.72%+14.80%+30.86% 2.46TCr
+0.40%+12.51% - - 1.66TCr
+2.64%+6.00%+69.30%+127.40% 1.51TCr
-0.15%+4.94%+13.27%+17.71% 1.37TCr
-0.13%+3.49%+98.27%+92.77% 1.31TCr
Average +1.28%+7.11%+76.88%+102.00% 2.34TCr
Weighted average by Cap. +1.82%+7.40%+94.26%+137.35%

Financials

2026 *2027 *
Net sales 1.79Cr 1.57Cr 1.45Cr 1.35Cr 2.55Cr 170.53Cr 2.6Cr 17Cr 6.76Cr 84Cr 6.73Cr 6.59Cr 291.32Cr 1.81Cr 1.59Cr 1.46Cr 1.36Cr 2.57Cr 172.01Cr 2.62Cr 18Cr 6.81Cr 84Cr 6.79Cr 6.65Cr 293.85Cr
Net income -2.38Cr -2.09Cr -1.92Cr -1.79Cr -3.38Cr -226.16Cr -3.45Cr -23Cr -8.96Cr -111.01Cr -8.93Cr -8.74Cr -386.35Cr -3.17Cr -2.78Cr -2.56Cr -2.38Cr -4.5Cr -301Cr -4.59Cr -31Cr -12Cr -147.75Cr -12Cr -12Cr -514.21Cr
Net Debt - -
Logo Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing cell replacement therapies to treat serious medical conditions. The Company programs are based on a cell-based technology platform, AlloSCOPE, which develops formulation, manufacturing, and delivery capabilities, and serves as the source of its pluripotent cell-based product candidates. Its pipeline includes OpRegen, an allogeneic retinal pigment epithelial (RPE) cell replacement therapy for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (dry-AMD); OPC1, an allogeneic oligodendrocyte progenitor cell therapy for the treatment of spinal cord injuries (SCI); ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant therapy for the treatment of auditory neuropathy; ILT1, an allogeneic cell transplant research initiative for the treatment of Type 1 Diabetes (T1D).
Employees
75
Date Price Change Volume
02/26/02 $1.300 -0.76% 7,73,847
30/26/30 $1.310 -2.96% 8,65,791
29/26/29 $1.350 +5.47% 14,68,523
26/26/26 $1.280 +4.92% 2,25,39,712
25/26/25 $1.220 -3.17% 11,59,013
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
1.310USD
Average target price
5.500USD
Spread / Average Target
+319.85%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. LCTX Stock